Super Performance Candidate

HIMS , explosive revenue and subscriber growth; already exceeding guidance, dominance in high growth telehealth and lifestyle drug markets with relentless innovation
At a RS Rating of 98,
I have reasons to believe that this equity can increase in price
(Now in white chart canvas!)